3 of 9
Gilead Sciences
(GILD) P/E: 13.0, EPS Growth: 14%

With its booming double-digit growth and sweet quarterly surprises, Gilead will cure your fear of commitment to biotechnology stocks in no time.

One of the world's leading makers of AIDS medications, Gilead caught our attention when it posted fourth-quarter sales that were up 42% from a year ago after better than expected sales of its most popular HIV drug, Atripla.

Hamed Khorsand, an analyst at BWS Financial, said Gilead has "the safest and most effective treatment for HIV" and that should continue to fuel growth.

After its record fourth quarter earnings, Gilead raised its sales forecast and now expects growth of 17% to 19% from 2009.

And what's more attractive than a little self-confidence? Because of Gilead's healthy cash flow, the company said it will buy back up to $1 billion of its common stock in the next year.

Best of all, Gilead is a cheap date considering its impressive balance sheet and consistent growth. The company's stock is trading at 13 times its estimated 2010 earnings per share, right in line with the industry average.

--Blake Ellis

NEXT: Franklin Resouces

Last updated February 13 2010: 11:57 AM ET
Email | Print | Share  |  RSS
google my aol my msn my yahoo! netvibes
Paste this link into your favorite RSS desktop reader
See all CNNMoney.com RSS FEEDS (close)
More Galleries
10 of the most luxurious airline amenity kits When it comes to in-flight pampering, the amenity kits offered by these 10 airlines are the ultimate in luxury More
7 startups that want to improve your mental health From a text therapy platform to apps that push you reminders to breathe, these self-care startups offer help on a daily basis or in times of need. More
5 radical technologies that will change how you get to work From Uber's flying cars to the Hyperloop, these are some of the neatest transportation concepts in the works today. More

Special Offer

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2018 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc. 2018. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2018 and/or its affiliates.